RecruitingNot ApplicableNCT05794880

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Matched Unrelated Donor and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha/Beta T-Cell and B-Cell Depletion for Patients With Hematologic Malignancies With Targeted ATG Dosing Pilot Study, IDE 13641

Sponsor

Medical College of Wisconsin

Enrollment

40 participants

Start Date

May 1, 2023

Study Type

INTERVENTIONAL

Conditions

Leukemia Acute Myeloid Leukemia in Remission Lymphoblastic Lymphoma Burkitt Lymphoma Chronic Myelogenous Leukemia - Chronic Phase Biphenotypic Acute Leukemia Myelodysplasia Acute Lymphoblastic Leukemia in Remission Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia With Crisis of Blast Cells Burkitt Leukemia Lymphoma After Relapse Other Malignant Hematologic Diseases in Remission

Summary

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival

Eligibility

Min Age: 0 YearsMax Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a specialized bone marrow transplant approach in children and young adults with leukemia or related blood cancers. It uses a targeted method to reduce transplant complications by removing specific immune cells from the donor's cells before transplant. **You may be eligible if...** - You are under 25 years old - You have been diagnosed with a blood cancer such as AML, ALL, MDS, CML, or a related condition - Your disease is in remission with no detectable cancer cells (MRD-negative) or in a stable phase - Other specific disease and donor-matching criteria apply **You may NOT be eligible if...** - Your cancer is not in remission or does not meet the disease-status criteria - You do not have a suitable bone marrow donor - You have other significant health conditions your doctor will review Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMagnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

Participants in this study will receive a blood stem cell transplant, which will use an investigational device called the CliniMACs device to remove alpha/beta T cells and B cells from the blood cells collected from the donor. This is called T cell depletion and B cell depletion.

Locations(1)

Children's Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05794880

Related Trials

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT052379863 locations

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

NCT055363491 location

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

NCT065337482 locations

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

NCT062896733 locations

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247288 locations